Connect Biopharma Holdings Limited

NASDAQ:CNTB

Biotechnology

Healthcare
$0.80 -4.09%

-$0.09 today

Market cap
$50.52M
Beta
-0.21
P/E (TTM)
-4.0
EPS (TTM)
-$0.50
52W Low $0.91High $3.82

Volume 2.50M

Average 0.30M

CNTB Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Connect Biopharma Holdings LimitedNASDAQ: CNTB

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization grows 14.6% year over year

Q4 FY2025 depreciation & amortization of $181K rose 14.6% year over year. Over 3 fiscal years it compounded at -11.9% a year.

Context

  • Depreciation & amortization amounted to 1100.0% of revenue in FY2025, up 1097.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$181K— QoQ
Last fiscal yearDec 2025
$704K+6.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.6%——
1 year+6.7%——
3-year CAGR-11.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
704K USD
Year-over-year change
+6.7%
4-year CAGR
+2.7%

Depreciation & Amortization vs competitors

How CNTB compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.7% is the 3rd highest of 8, against a peer median of -3.9%.
  • Depreciation & amortization amounts to 1100.0% of revenue for CNTB, versus a peer median of 185.5%.
CNTB Competitors
Depreciation & Amortization for CNTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%-4.0%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.64M USD+6.6%+30.9%—
IMAImageneBio IncLTM Mar 2026$822K USD+129.6%+11.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.9%1100.0%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
OVIDOvid Therapeutics Inc.LTM Mar 2026$167K USD-73.0%-39.9%2.3%
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
Peer median (excluding CNTB) —-3.9%+6.3%185.5%

Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00026.03M64K
Cost of Revenue00000
Gross Profit00026.03M64K
Gross Margin———100.0%100.0%
Research & Development80.5M96.63M53M29.26M37.8M
Selling, General & Admin19.01M20.81M16.05M19.23M20.34M
Operating Expenses98.11M119.32M69.06M48.49M58.14M
Depreciation & Amortization634K1.03M720K660K704K
EBITDA(201.36M)(116.74M)(61.27M)(14.75M)(54.58M)
EBITDA Margin———-56.6%-85279.7%
Operating Income(98.11M)(119.32M)(69.06M)(22.45M)(58.07M)
Operating Margin———-86.2%-90740.6%
Interest Income97.67K1.56M5.2K4.45M2.27M
Interest Expense6.91K21.03K000
Other Income / Expenses(103.89M)1.52M7.07M7.05M2.79M
Income Before Tax(202M)(117.79M)(61.99M)(15.41M)(55.28M)
Pre-Tax Margin———-59.2%-86379.7%
Income Tax Expense266K298K120K223K197K
Net Income(202.27M)(118.09M)(62.11M)(15.63M)(55.48M)
Net Margin———-60.0%-86687.5%
EPS (Basic)(25.00)(14.50)(1.08)(0.28)(1.00)
EPS (Diluted)(25.00)(14.50)(1.08)(0.28)(1.00)
Weighted Avg Shares52.27M55.04M55.07M55.21M55.66M
Weighted Avg Shares (Diluted)52.27M55.04M55.07M55.21M55.66M

Connect Biopharma Holdings Limited

NASDAQ:CNTB

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.